• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MetaVia Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/8/26 4:00:57 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTVA alert in real time by email
    false 0001638287 0001638287 2026-06-08 2026-06-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 8, 2026

     

     

    METAVIA INC.

    (Exact name of Registrant as Specified in Its Charter)

     

    Delaware 001-37809 47-2389984
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
         

    545 Concord Avenue, Suite 210

    Cambridge, Massachusetts

    (Address of principal executive offices)

      02138
    (Zip Code)

     

    (857) 702-9600

    (Registrant’s telephone number, including area code)

     

    Not applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

      

    Title of each class  

    Trading
    Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share   MTVA   The Nasdaq Stock Market LLC

      

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company  ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

     

    Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On June 8, 2026, at the 2026 virtual annual meeting of stockholders (the “Annual Meeting”) of MetaVia Inc. (the “Company”), the stockholders of the Company approved the first amendment (the “First Amendment”) to the MetaVia Inc. 2022 Amended and Restated Equity Incentive Plan, as amended on November 29, 2024 (the “2022 Equity Incentive Plan”), which was previously approved by the Board of Directors of the Company. The First Amendment became effective upon stockholder approval, and provides for an increase in the aggregate number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), that may be issued pursuant to the 2022 Equity Incentive Plan by 200,000 shares.

     

    Except as amended by the First Amendment, the other terms of the 2022 Equity Incentive Plan remain in full force and effect. A description of the terms of the First Amendment and 2022 Equity Incentive Plan is included in “Proposal 4 Approval of the First Amendment to Our 2022 Equity Incentive Plan” in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 27, 2026 (the “Proxy Statement”), which description is incorporated herein by reference. Such description is a summary only and is qualified in its entirety by reference to the full text of the First Amendment and 2022 Equity Incentive Plan included in such definitive proxy statement. The First Amendment is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

     

    Item 5.07Submission of Matters to a Vote of Security Holders.

     

    On June 8, 2026, the Company held its Annual Meeting, whereby the Company’s stockholders voted on five proposals at the Annual Meeting as set forth below, each of which is described in more detail in the Proxy Statement. There were 2,866,545 shares of Common Stock present and entitled to vote at the Annual Meeting, online or by proxy, which constituted a quorum for the transaction of business. In deciding the proposals at the Annual Meeting, each share of Common Stock represented one vote.

     

    At the Annual Meeting, the Company’s stockholders voted on the following proposals:

     

      1. To elect two Class I directors, each to serve a three-year term until the 2029 annual meeting of stockholders and until the election and qualification of such director’s successor, or such director’s earlier death, resignation, or removal (the “Class I Directors Proposal”);

     

      2. To ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026;

     

      3. To approve an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse split of the Company’s outstanding Common Stock at a ratio in the range of 1-for-5 to 1-for-22 to be determined at the discretion of the Company’s  Board of Directors, whereby each outstanding 5 to 22 shares of Common Stock would be combined, converted and changed into one share of  the Company’s Common Stock (the “Reverse Stock Split Proposal”);

     

      4. To approve the First Amendment to the 2022 Equity Incentive Plan to increase the aggregate number of shares of Common Stock that may be issued pursuant to awards by 200,000 shares of Common Stock (the “Equity Plan Proposal”); and

     

      5. To authorize one or more adjournments of the Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposals 3 and 4 described above (the “Adjournment Proposal”).

     

    The voting results at the Annual Meeting are shown below:

     

    Proposal 1—The Class I Directors Proposal.

     

    Class I Nominees  Votes For  Votes Withheld  Broker Non-Votes
    D. Gordon Strickland  1,927,368  7,372  931,805
    James P. Tursi, M.D.  1,926,735  8,005  931,805

     

     

     

     

    D. Gordon Strickland and James P. Tursi, M.D. were elected as Class I directors to serve until the 2029 annual meeting of stockholders.

     

    Proposal 2—Ratification of the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

     

    Votes For  Votes Against  Abstentions
    2,772,109  89,718  4,718

     

    The stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. There were no broker non-votes on this matter.

     

    Proposal 3— The Reverse Stock Split Proposal.

     

    Votes For  Votes Against  Abstentions
    2,472,949  373,239  20,357

     

    The stockholders approved the Reverse Stock Split Proposal. There were no broker non-votes on this matter.

     

    Proposal 4—The Equity Plan Proposal.

     

    Votes For  Votes Against  Abstentions  Broker Non-Votes
    1,893,233  35,799  5,708  931,805

     

    The stockholders approved the Equity Plan Proposal.

     

    Proposal 5—The Adjournment Proposal.

     

    Votes For  Votes Against  Abstentions  Broker Non-Votes
    1,902,616  29,372  2,752  931,805

     

    The stockholders approved the Adjournment Proposal.

     

    Item 9.01.Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit
    Number
      Exhibit Description
    10.1   First Amendment to the MetaVia Inc. Amended and Restated 2022 Equity Incentive Plan.
    104   Cover Page Interactive Data File (embedded within Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      METAVIA INC.
       
    Date: June 8, 2026 By: /s/ Hyung Heon Kim
        Hyung Heon Kim
        President and Chief Executive Officer

     

     

     

    Get the next $MTVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTVA

    DatePrice TargetRatingAnalyst
    9/4/2025$12.00Buy
    H.C. Wainwright
    12/30/2024$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $MTVA
    SEC Filings

    View All

    SEC Form S-8 filed by MetaVia Inc.

    S-8 - MetaVia Inc. (0001638287) (Filer)

    6/8/26 4:30:42 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - MetaVia Inc. (0001638287) (Filer)

    6/8/26 4:00:57 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - MetaVia Inc. (0001638287) (Filer)

    6/8/26 9:01:47 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tursi James Patrick was granted 17,186 shares, increasing direct ownership by 508% to 20,568 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/8/26 6:33:59 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strickland D Gordon was granted 17,186 shares, increasing direct ownership by 414% to 21,339 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/8/26 6:33:28 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Salsbury Michael was granted 17,186 shares, increasing direct ownership by 414% to 21,338 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/8/26 6:32:08 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Woodworth Marshall H bought $9,940 worth of shares (14,200 units at $0.70), increasing direct ownership by 47% to 44,279 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/4/25 4:01:12 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Dong-A St Co., Ltd bought $3,300,000 worth of shares (4,647,887 units at $0.71), increasing direct ownership by 87% to 9,995,679 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    5/20/25 4:16:39 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

    DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of PlateauVanoglipel Combined with Resmetirom Demonstrated Synergistic Hepatoprotective and Weight-Loss Effects in Preclinical MASH ModelVanoglipel Combined with Metformin Demonstrated Enhanced Glycemic Control and Body Weight Reduction Versus Monotherapy in a Preclinical T2D ModelCAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at the American Diabetes Associati

    6/8/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

    CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present an update highlighting the company's pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Thursday, June 11, 2026 at 3:25 pm ET. After the presentation, MetaVia's management will open the floor for questions. Attendees may submit questions in advance to questions@emerginggrowth.com, or ask questi

    6/4/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

    48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of PlateauExploratory FibroScan Assessments Demonstrated Early Liver-Related ImprovementsOngoing Phase 1 Part 3a/3b Titration Studies Continue to Evaluate Extended Treatment at Higher-Dose LevelsCAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new Phase 1 data on DA-1726, a novel dual oxyntomodulin (OXM) analog agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), in a late-breaking poster presentation at the European Ass

    5/27/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on MetaVia with a new price target

    H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    9/4/25 9:02:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on MetaVia with a new price target

    H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    12/30/24 7:25:48 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Leadership Updates

    Live Leadership Updates

    View All

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

    CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Thursday, March 12, 2026 at 10:30 am ET. This will be a live, interactive online event where investors are invited to ask the company questions

    3/4/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care